Message Font: Serif | Sans-Serif
No. of Recommendations: 0
SNTA (synta pharma)

hsp inhibitor, generating investor noise, their second med has one good thing and one negative going for it- (positive- has biomarker that correlates with disease progress/regression ... negative- novel mechanism).

results for the hsp inhibitor due in 2013, though interim in july 2012.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.